Skip to main content

Table 4 Factors associated with receiving treatment among HPV positive, triage positive women in Nicaragua in 2017

From: HPV-based cervical cancer screening in Nicaragua: from testing to treatment

 Not treated
(N = 429)
Treated
(N = 486)
n (%)n (%)Unadjusted Prevalence ORa (95%CI)Adjusted Prevalence ORb (95%CI)Treatment Ratio
Province
 Carazo50 (29.2)121 (70.7)RefRefRef
 Chinandega199 (70.1)85 (29.9)0.18 (0.12–0.27)*0.34 (0.20–0.56)*0.42
 Chontales180 (39.1)280 (60.9)0.64 (0.44–0.94)**0.67 (0.42–1.07)0.86
Age, years
 < 305 (55.6)4 (44.4)RefRefRef
 30–39247 (44.3)311 (55.7)1.57 (0.42–5.92)1.26 (0.21–7.77)1.25
 40–49102 (46.4)118 (53.6)1.44 (0.38–5.52)1.37 (0.22–8.59)1.21
 50–5971 (57.3)53 (42.7)0.93 (0.24–3.64)1.13 (0.18–7.27)0.96
 60+4 (100.0)0 (0)NANANA
 Unknown     
HPV Screening Modality
 Self-collected420 (46.8)477 (53.2)RefRefRef
 Provider-collected9 (52.9)8 (47.1)0.78 (0.30–2.04)1.11 (0.37–3.32)0.89
 Unknown0 (0)1 (100.0)NANA1.88
Triage Method
 VIA48 (11.9)354 (88.1)RefRefRef
 Pap381 (74.3)132 (25.7)0.05 (0.03–0.07)*0.05 (0.04–0.08)*0.29
  1. Abbreviations: HPV Human papillomavirus, CI confidence interval, OR odds ratio, Ref Reference category, NA not applicable, VIA visual inspection with acetic acid
  2. *P values < 0.001
  3. **P value = 0.022
  4. aUnadjusted odds ratio for the association between each risk factor and treated
  5. bAdjusted odds ratio for all the listed factors